Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial

Related

• 

  Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID

  W. Lloyd Clark, MD, FASRS

  Annual Meeting Talks

  2021

• 

  Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study

  Ananda Kalevar, MD, FRCS(C), DABO

  On Demand Cases, Courses, and Papers

  2020

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024